Longevity & AgingResearch PaperPaywall

Metformin May Heal Skin Through the Gut and Immune System

A new review explores how metformin's effects on gut bacteria and immunity could help treat eczema, psoriasis, wound healing, and skin aging.

Friday, November 13, 2026 1 view
Published in Pharmacol Rep
Metformin molecule floating above glowing gut bacteria with a translucent skin cross-section and immune cells in teal tones

Summary

Metformin, a widely prescribed type 2 diabetes drug, is being studied for uses well beyond blood sugar control. This narrative review from Jagiellonian University examines how metformin may help in skin conditions such as atopic dermatitis, allergic contact dermatitis, and psoriasis, and how it may influence skin aging and wound healing. The authors propose two linked mechanisms: metformin's immunomodulatory actions and its ability to reshape gut microbiota composition. By summarizing current evidence on how the drug affects gut microbes and immune function, the review frames the gut-skin axis as a possible route through which a familiar, inexpensive medication might benefit the skin. Based on the abstract alone, the paper offers a synthesis of existing research rather than new trial data, so it points to promising directions rather than proven treatments for skin disease.

Detailed Summary

Metformin is a first-line therapy for type 2 diabetes, and interest in repurposing it for aging-related and inflammatory conditions keeps growing. Skin diseases are common, chronic, and often hard to control, so a low-cost drug with a long safety record is an attractive candidate.

This review from Jagiellonian University Medical College summarizes existing evidence on how metformin affects gut microbial composition and the immune system, and how those effects might relate to skin disease. The abstract notes that metformin is already used in managing atopic dermatitis, allergic contact dermatitis, and psoriasis, and that it has been linked to changes in skin aging and improved wound healing.

The central idea is that metformin's skin benefits may not stem solely from its glucose-lowering action. Instead, they may arise from immunomodulation and from shifts in gut microbiota that influence systemic inflammation, a concept often called the gut-skin axis. The abstract also notes metformin's broader potential in chronic pain, cancer, and polycystic ovary syndrome.

For clinicians and longevity-minded readers, the review reinforces metformin as a multi-target drug whose effects reach the microbiome and immune signaling. It may help guide future research into microbiome-informed dermatologic therapy.

Several caveats apply. Only the abstract was available, so specific findings, effect sizes, and the quality of the underlying studies cannot be assessed. The review is a narrative synthesis, not a trial, and does not establish that metformin is an effective skin treatment in people without diabetes. Much of the mechanistic evidence likely comes from animal or small human studies, and it remains unclear whether the gut microbiota changes actually cause skin improvement.

Key Findings

  • Metformin is reported to be used in managing atopic dermatitis, allergic contact dermatitis, and psoriasis.
  • Metformin may influence skin aging processes and promote wound healing, according to the review.
  • Proposed mechanisms include immunomodulation and changes in gut microbiota composition.
  • Beyond diabetes, metformin shows potential in chronic pain, cancer, and polycystic ovary syndrome.
  • The review synthesizes evidence on metformin's effects on both gut microbes and the immune system.

Methodology

This is a narrative review summarizing existing literature on metformin, gut microbiota, immune responses, and skin disease. The abstract does not describe a systematic search strategy, inclusion criteria, or quality appraisal. Only the abstract was available for this analysis.

Study Limitations

Only the abstract was reviewed, so the strength of evidence, study types, and specific results are unknown. As a narrative review, it may be subject to selection bias and cannot demonstrate causation between microbiota changes and skin outcomes. Dosing, patient populations, and safety in non-diabetic people with skin disease are not addressed in the abstract.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: